Emoxypine Succinate (Mexidol) 125 mg – 60 Capsules

Ηλεκτρική εμοξιπίνη / Mexidol 125 mg — 60 ερευνητικές κάψουλες από του στόματος. Emoxypine succinate (Mexidol) is the most extensively prescribed nootropic-antioxidant compound in the entire post-Soviet pharmaceutical market — the subject of more than 700 published clinical studies και routine clinical use in the Russian Federation και several CIS countries for cerebrovascular disease, vascular cognitive impairment, anxiety disorders και post-traumatic recovery. Pharmacologically, it pairs the structural antioxidant scaffold of emoxypine — a synthetic vitamin-B6 analogue of pyridoxine — with the mitochondrial substrate succinate, producing a hybrid molecule whose mechanism integrates membrane-stabilizing antioxidant activity with direct mitochondrial-respiratory-chain support.

Επισκόπηση έρευνας

Emoxypine (2-ethyl-6-methyl-3-hydroxypyridine) is a synthetic 3-hydroxypyridine derivative — structurally a vitamin-B6 (pyridoxine) analogue — developed at the Russian Academy of Medical Sciences in the 1960s as a membrane-stabilizing antioxidant [1]. Its succinate salt form (Mexidol) was introduced in the 1980s και combines the antioxidant activity of the emoxypine scaffold with the direct mitochondrial-substrate effects of succinic acid — a TCA-cycle intermediate that bypasses Complex I of the electron transport chaσεnd donates electrons directly to Complex II, παρέχοντας rescue capacity in conditions of Complex I dysfunction [1,2]. Mexidol is one of the most prescribed nootropic / cerebroprotective compounds in the entire post-Soviet pharmaceutical market, with more than 700 published clinical studies covering acute και chronic ischemic stroke, vascular cognitive impairment, dyscirculatory encephalopathy, generalized anxiety disorder, alcohol-withdrawal syndromes και traumatic brain injury [2,3]. Mechanisms of action documented σεnimal models include: direct lipid-peroxidation inhibition, GABA-A receptor positive allosteric modulation (the basis of the anxiolytic phenotype), mitochondrial-membrane stabilization, και benzodiazepine-receptor-independent anxiolysis with no measurable sedation, dependence or cognitive impairment.

Κύριοι τομείς έρευνας

• Cerebrovascular και ischemic-stroke research — the principal Russian-clinical-literature indication; investigated σεcute και chronic cerebral ischemia models with reproducible neuroprotective signals [1,2].
• Μιτοχονδριακή βιοενεργητική — the succinate moiety provides Complex-II-direct electron donation, with rescue capacity in Complex-I-deficient mitochondrial models [2].
• Αγχολυτική φαρμακολογία — GABA-A positive allosteric modulation produces anxiolysis without the sedation, dependence or cognitive impairment of classical benzodiazepines [3].
• Αγγειακή γνωστική έκπτωση — the principal contemporary clinical-research indication in CIS countries; investigated in dyscirculatory encephalopathy και post-stroke cognitive recovery [2].
• Antioxidant και membrane-stabilization research — documented direct lipid-peroxidation inhibition και mitochondrial-membrane-stabilization activity at physiological concentrations [1].

Βιβλιογραφία

1. Voronina TA. Mexidol: spectrum of pharmacological activity. Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112(12):86–90.
2. Skvortsova VI, Stakhovskaya LV, Nartsissov YR, et al. A rκαιomized, double-blind, placebo-controlled study of mexidol use in ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2006;Suppl 18:47–54.
3. Voronina TA, Yarkova MA, Belyy VP. Anxiolytic activity of the new pyridine derivative mexidol. Eksp Klin Farmakol. 2013;76(7):3–6.